ChloroquineV1, Main, Exploration, bibRecord, 001026

Cytotoxic agents in sarcoidosis: which one should we choose?

Identifieur interne : 001026 ( Main/Exploration ); précédent : 001025; suivant : 001027

Cytotoxic agents in sarcoidosis: which one should we choose?

Auteurs : Adriane D M. Vorselaars ; Johanna P. Cremers ; Jan C. Grutters ; Marjolein Drent

Source :

Current opinion in pulmonary medicine [ 1531-6971 ] ; 2014.

RBID : pubmed:25046427

Descripteurs français

KwdFr :
- Cytotoxines (usage thérapeutique), Facteur de nécrose tumorale alpha (antagonistes et inhibiteurs), Humains, Immunosuppresseurs (usage thérapeutique), Sarcoïdose (traitement médicamenteux).
MESH :
- antagonistes et inhibiteurs : Facteur de nécrose tumorale alpha.
- traitement médicamenteux : Sarcoïdose.
- usage thérapeutique : Cytotoxines, Immunosuppresseurs.
- Humains.

English descriptors

KwdEn :
- Cytotoxins (therapeutic use), Humans, Immunosuppressive Agents (therapeutic use), Sarcoidosis (drug therapy), Tumor Necrosis Factor-alpha (antagonists & inhibitors).
MESH :
- chemical , antagonists & inhibitors : Tumor Necrosis Factor-alpha.
- chemical , therapeutic use : Cytotoxins, Immunosuppressive Agents.
- drug therapy : Sarcoidosis.
- Humans.

Abstract

Sarcoidosis is a granulomatous disease which affects multiple organs. Its therapeutic management is very challenging due to the heterogeneity in disease manifestation and clinical course, as well as the potential side effects of the immunosuppressive therapy. An overview of presently available second-line and third-line systemic agents is provided.

DOI: 10.1097/MCP.0000000000000078
PubMed: 25046427

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cytotoxic agents in sarcoidosis: which one should we choose?</title>
<author><name sortKey="Vorselaars, Adriane D M" sort="Vorselaars, Adriane D M" uniqKey="Vorselaars A" first="Adriane D M" last="Vorselaars">Adriane D M. Vorselaars</name>
<affiliation><nlm:affiliation>aCentre of Interstitial Lung Diseases, Department of Pulmonology, St Antonius Hospital, Nieuwegein bild care expertise team, Department of Respiratory Medicine, Hospital Gelderse Vallei, Ede cDepartment of Internal Medicine, Atrium Medical Centre, Heerlen dDivision of Heart and Lungs, University Medical Centre Utrecht, Utrecht eDepartment of Toxicology, Faculty of Health, Medicine and Life Sciences (FHML), University Maastricht, Maastricht, The Netherlands *Adriane D.M. Vorselaars and Johanna P. Cremers contributed equally to the writing of this article.</nlm:affiliation>
<wicri:noCountry code="subField">The Netherlands *Adriane D.M.</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Cremers, Johanna P" sort="Cremers, Johanna P" uniqKey="Cremers J" first="Johanna P" last="Cremers">Johanna P. Cremers</name>
</author>
<author><name sortKey="Grutters, Jan C" sort="Grutters, Jan C" uniqKey="Grutters J" first="Jan C" last="Grutters">Jan C. Grutters</name>
</author>
<author><name sortKey="Drent, Marjolein" sort="Drent, Marjolein" uniqKey="Drent M" first="Marjolein" last="Drent">Marjolein Drent</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:25046427</idno>
<idno type="pmid">25046427</idno>
<idno type="doi">10.1097/MCP.0000000000000078</idno>
<idno type="wicri:Area/PubMed/Corpus">000287</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000287</idno>
<idno type="wicri:Area/PubMed/Curation">000287</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000287</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000296</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000296</idno>
<idno type="wicri:Area/Ncbi/Merge">000256</idno>
<idno type="wicri:Area/Ncbi/Curation">000256</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000256</idno>
<idno type="wicri:Area/Main/Merge">001027</idno>
<idno type="wicri:Area/Main/Curation">001026</idno>
<idno type="wicri:Area/Main/Exploration">001026</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Cytotoxic agents in sarcoidosis: which one should we choose?</title>
<author><name sortKey="Vorselaars, Adriane D M" sort="Vorselaars, Adriane D M" uniqKey="Vorselaars A" first="Adriane D M" last="Vorselaars">Adriane D M. Vorselaars</name>
<affiliation><nlm:affiliation>aCentre of Interstitial Lung Diseases, Department of Pulmonology, St Antonius Hospital, Nieuwegein bild care expertise team, Department of Respiratory Medicine, Hospital Gelderse Vallei, Ede cDepartment of Internal Medicine, Atrium Medical Centre, Heerlen dDivision of Heart and Lungs, University Medical Centre Utrecht, Utrecht eDepartment of Toxicology, Faculty of Health, Medicine and Life Sciences (FHML), University Maastricht, Maastricht, The Netherlands *Adriane D.M. Vorselaars and Johanna P. Cremers contributed equally to the writing of this article.</nlm:affiliation>
<wicri:noCountry code="subField">The Netherlands *Adriane D.M.</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Cremers, Johanna P" sort="Cremers, Johanna P" uniqKey="Cremers J" first="Johanna P" last="Cremers">Johanna P. Cremers</name>
</author>
<author><name sortKey="Grutters, Jan C" sort="Grutters, Jan C" uniqKey="Grutters J" first="Jan C" last="Grutters">Jan C. Grutters</name>
</author>
<author><name sortKey="Drent, Marjolein" sort="Drent, Marjolein" uniqKey="Drent M" first="Marjolein" last="Drent">Marjolein Drent</name>
</author>
</analytic>
<series><title level="j">Current opinion in pulmonary medicine</title>
<idno type="eISSN">1531-6971</idno>
<imprint><date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cytotoxins (therapeutic use)</term>
<term>Humans</term>
<term>Immunosuppressive Agents (therapeutic use)</term>
<term>Sarcoidosis (drug therapy)</term>
<term>Tumor Necrosis Factor-alpha (antagonists & inhibitors)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Cytotoxines (usage thérapeutique)</term>
<term>Facteur de nécrose tumorale alpha (antagonistes et inhibiteurs)</term>
<term>Humains</term>
<term>Immunosuppresseurs (usage thérapeutique)</term>
<term>Sarcoïdose (traitement médicamenteux)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Tumor Necrosis Factor-alpha</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Cytotoxins</term>
<term>Immunosuppressive Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Facteur de nécrose tumorale alpha</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Sarcoidosis</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Sarcoïdose</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Cytotoxines</term>
<term>Immunosuppresseurs</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Humains</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Sarcoidosis is a granulomatous disease which affects multiple organs. Its therapeutic management is very challenging due to the heterogeneity in disease manifestation and clinical course, as well as the potential side effects of the immunosuppressive therapy. An overview of presently available second-line and third-line systemic agents is provided.</div>
</front>
</TEI>
<affiliations><list></list>
<tree><noCountry><name sortKey="Cremers, Johanna P" sort="Cremers, Johanna P" uniqKey="Cremers J" first="Johanna P" last="Cremers">Johanna P. Cremers</name>
<name sortKey="Drent, Marjolein" sort="Drent, Marjolein" uniqKey="Drent M" first="Marjolein" last="Drent">Marjolein Drent</name>
<name sortKey="Grutters, Jan C" sort="Grutters, Jan C" uniqKey="Grutters J" first="Jan C" last="Grutters">Jan C. Grutters</name>
<name sortKey="Vorselaars, Adriane D M" sort="Vorselaars, Adriane D M" uniqKey="Vorselaars A" first="Adriane D M" last="Vorselaars">Adriane D M. Vorselaars</name>
</noCountry>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001026 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001026 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:25046427
   |texte=   Cytotoxic agents in sarcoidosis: which one should we choose?
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:25046427" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a ChloroquineV1

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021

Serveur d'exploration Chloroquine

Cytotoxic agents in sarcoidosis: which one should we choose?

Cytotoxic agents in sarcoidosis: which one should we choose?

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration Chloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.